Clinical Trial Update: NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating NK010 or NK042 in combination with Rituximab for refractory systemic lupus erythematosus and refractory lupus nephritis is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• NK010
• NK042
• Rituximab (rituximab)

Snippet

Sponsor: Guangdong Provincial People's Hospital | Conditions: Refractory Systemic Lupus Erythematosus, Refractory Lupus Nephritis | Phase 1 | Status: RECRUITING